NCT02679131 - To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions

Relapsed/Refractory Solid Tumors/Hematological Malignancies

Interventions

DRUG

Belinostat

Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.

Trial Locations (2)

Gabrail Cancer Center Research, Canton

Innovative Clinical Research Institute, Whittier